PARP Inhibitors, Vaccines, and Combos Spark Excitement in mRCC
Published: Thursday, Jan 09, 2020
Sumanta K. Pal, MD
PARP inhibitors, CAR-based products, vaccines, and novel combination strategies are poised for introduction to the field of metastatic renal cell carcinoma (mRCC), said Sumanta Kumar Pal, MD.
... to read the full story